Compare AU

Compare BNDS vs. CURE

Compare shares and ETFs on the ASX that you can trade on Pearler.

BetaShares Westn Asset Aus Bond Fund (Managed Fund)

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Westn Asset Aus Bond Fund (Managed Fund) (BNDS) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

BNDS

CURE

Popularity

Low

Low

Pearlers invested

13

83

Median incremental investment

$625.59

$619.50

Median investment frequency

Monthly

Monthly

Median total investment

$922.35

$1,475.04

Average age group

> 35

> 35


Key Summary

BNDS

CURE

Strategy

BNDS.AX was created on 2018-11-07 by BetaShares. The fund's investment portfolio concentrates primarily on broad credit fixed income. The Fund aims to earn an after fee return in excess of the Bloomberg AusBond Composite 0+yr Index over rolling three year periods.

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

Top 3 holdings

AUSTRALIAN GOVERNMENT 2.75% MAY-41 (2.45 %)

AUSTRALIAN GOVERNMENT 1.75% NOV-32 (1.70 %)

AUSTRALIAN GOVERNMENT 3.75% MAY-34 (1.54 %)

Natera Inc (3.33 %)

Incyte Corp (2.95 %)

Gilead Sciences Inc (2.81 %)

Top 3 industries

Other (99.56 %)

Communication Services (0.44 %)

Health Care (100.00 %)

Other (10.24 %)

Top 3 countries

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

Management fee

0.42 %

0.45 %


Key Summary

BNDS

CURE

Issuer

BetaShares

Global X

Tracking index

Bloomberg AusBond Composite Index - AUD

S&P Biotechnology Select Industry

Asset class

ETF

ETF

Management fee

0.42 %

0.45 %

Price

$23.65

$52.68

Size

$756.531 million

$36.301 million

10Y return

N/A

N/A

Annual distribution yield (5Y)

2.47 %

4.24 %

Market

ASX

ASX

First listed date

16/11/2018

12/11/2018

Purchase fee

$6.50

$6.50


Community Stats

BNDS

CURE

Popularity

Low

Low

Pearlers invested

13

83

Median incremental investment

$625.59

$619.50

Median investment frequency

Monthly

Monthly

Median total investment

$922.35

$1,475.04

Average age group

> 35

> 35


Pros and Cons

BNDS

CURE

Pros

  • Lower management fee

  • Higher exposure to US market

  • Higher price growth

  • Higher distribution yield

Cons

  • Lower exposure to US market

  • Lower price growth

  • Lower distribution yield

  • Higher management fee

BNDS

CURE

Lower exposure to US market

Higher exposure to US market

Lower management fee

Higher management fee

Lower price growth

Higher price growth

Lower distribution yield

Higher distribution yield

Home